Altimmune announces update on adcovid™ phase 1 clinical trial

Gaithersburg, md., june 29, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today provided an update on its adcovid investigational vaccine for the prevention of covid-19. the company also provided an update on its t-covid phase 1/2 clinical trial to evaluate the potential of t-covid to prevent clinical worsening in patients with early covid-19.
ALT Ratings Summary
ALT Quant Ranking